A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advancedor Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation
Sponsor: Astellas Pharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU1524
U.S. Govt. ID: NCT05382559
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Cancers include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, kidney cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a advanced solid tumor with a KRAS G12D mutation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator